TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01729910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent education / behavioral counseling
Description: Providers and study personnel will be trained in the use of the NIH We Can! curriculum for group visits and brief motivational interviewing for individual visits and follow-up phone calls. Training will be conducted by the PI and Co-Investigators using a combination of online, self-study, and face-to-face formats totally at least/approximately 8 hours. At least one project team member will attend each group visit. Specifically, the American Academy of Pediatrics 15-minute Obesity Prevention Protocol will be utilized during individual visits. The intervention is designed to take place over a period of 10-12 weeks in the primary care office.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Parents of children in the control group will receive usual care from their primary care provider as well as a copy of the NIH We Can! Parent Handbook.
Study: NCT02648048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone will be administered as per the dosage schedule mentioned in arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Vismodegib will be administered as per the dosage schedule mentioned in arm description.
Study: NCT00679159

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Prevenar
Description: Streptococcus pneumoniae vaccine
Study: NCT02460822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyChemoCare iPad application
Study: NCT00303342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mind body treatment
Description: regulation of attention, respiration and posture

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: desensitization
Description: mentation on insomnia behaviors and cognitive activity
Study: NCT01241513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAC
Description: NAC provided to determine if beneficial at altitude

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00858702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil and a CCB
Description: olmesartan medoxomil tablets and a CCB tablet once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil and a diuretic
Description: olmesartan medoxomil tablets and a diuretic tablet, once daily for 8 weeks
Study: NCT00593554

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 8 Gy on Day -9

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiotepa
Description: 5 mg/kg/d on Day -8 to -7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 5 mg/kg/d on Day -8 to -7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 40 mg/m2/d on Day -6 to -3
Study: NCT01679665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 320U /0.5ml
Description: inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 4 weeks interval

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0/0.5ml placebo
Description: 0/0.5ml placebo, two doses, 4 weeks interval
Study: NCT00593554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m2/d on Day -6 to -3

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabbit ATG
Description: 2.5 mg/kg/d on Day -5 to -2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabbit ATG
Description: 2.5 mg/kg/d on Day -5 to -2
Study: NCT03134053

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: massage
Description: to treat painful and retracting scars
Study: NCT02247037

Intervention type: OTHER
Intervention: Chemotherapy
Description: Patients are treated with neoadjuvant chemotherapy as according to the standard of care guidelines. Patients with metastatic disease are treated according to standard of care guidelines.
Study: NCT00593554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: 60 ug/kg (actual body weight) on Day -9 to -7 and Day 0 to +2
Study: NCT01668875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head down 30 degree postural drainage position
Description: supine head down 30 degree on tilt table (intervention period in the treatment condition)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Horizontal supine lying
Description: horizontal supine lying on tilt table (intervention period in the sham condition)
Study: NCT04524182

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: There was no intervention in the control group during study.~At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: There was no intervention in the control group during study.~At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise
Study: NCT02596893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301
Study: NCT04524182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobilization group
Description: Lumbosacral mobilization for 10 minutes in the study group (pelvis forward and backward distraction, passive rotation of the lower body, short lever rotation, long lever rotation, lumbar central posterior-anterior, lumbar unilateral posterior-anterior, anterior rotation-posterior superior iliac spine- down, posterior rotation-posterior superior iliac spine-up were applied.~At the end of study all patients were received home-based exercise tailored to each individual's needs which include stretching, strengthening, balance and gait exercise and posture exercise
Study: NCT04270513

Intervention type: OTHER
Intervention: Endovascular treatment by Flying Intervention Team
Description: After telemedicine-assisted decision for endovascular treatment, the Flying Intervention Team is transferred via helicopter to the primary stroke center and performs endovascular treatment in the local angiography suite.
Study: NCT03356743

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectrum Analysis
Description: The ultrasound probe will be placed on the lung surface in several different directions to obtain the cross section with maximum diameter. Three spectral parameters including midband-fit (dB), intercept (dB), and slope (dB/MHz) will be calculated and compared between the tumor and the lung.
Study: NCT01411280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: Ritalin 10mg, Ritalin 20mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylphenidate
Description: Ritalin 10mg, Ritalin 20mg
Study: NCT00052949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01380522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Capsules, single-dose, fed
Study: NCT04509284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: The experimental group will perform a supervised progressive resistance training program, with five exercises for the upper- and lower body (box squat, bench press, trap bar deadlift, bench pull and lat pulldown), 2x/week for a 12 week period. The program will utilize a flexible progression system through three distinct training phases; 1) 2-4 sets of 10-12 repetitions, 2) 2-4 sets of 6-8 repetitions, 3) 2-4 sets of 2-4 repetitions. Number of sets are adjusted within session according to daily readiness while load is adjusted within and between sessions according to number of reps performed. A 3-5min rest period is provided throughout the program.
Study: NCT01380522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flagyl
Description: Capsules, single-dose, fed
Study: NCT01415245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluent (VGS Fluent external support device)
Description: Fluent external support device applied to saphenous vein graft
Study: NCT01817595

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BG Star Meter (Conventional) Internet Blood Glucose Reporting
Description: Patients in BG Star Meter Group will report using BG software through uploading information onto a computer and sending readings to their endocrinologist via email

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: iBG Star (iphone) Internet Blood Glucose Method
Description: 25 patients will be randomized to the iBGstar system will upload their readings to their iPhone and send in their readings using the iPhone.
Study: NCT00218322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine hydrochloride
Description: Atomoxetine up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
Study: NCT04509284

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The control group will be instructed to continue their everyday lifestyle with no specific instruction regarding exercise and/or diet. However, they will be encouraged not to engage in new forms of exercise or physical activity throughout the study period.
Study: NCT03152565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Autologous Dendritic Cells vaccine: A dose of ADC at days 1, 14, 28, 42 and 56 (total of 5 doses), and thereafter every 6 months until disease progression (maximum of 6 additional doses) or unacceptable toxicity.~Avelumab will be administered intravenously at a dose of 10 mg per kilogram of body weight, every 14 days until disease progression or unacceptable toxicity.
Study: NCT05324891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Infants received dexmedetomidine IV loading dose: 0.5 mcg/kg given over 20 minutes followed by maintenance dose 0.3 µg/kg/hour by infusion over 24 hours.Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Infants received Fentanyl IV continuous infusion: 1µg/ kg /hour. Weaning was done when the patient was about to be extubated or with maximum 5 days after the randomization.
Study: NCT01242124

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: side-to-side stapled esophagogastric anastomosis
Description: 20 patients of distal esophageal cancer receive side-to-side stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: circular-stapled esophagogastric anastomosis
Description: 20 patients of distal esophageal cancer receive circular-stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy
Study: NCT02311894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: Somatropin will be administered as SC injections at a dose of up to 0.043 mg/kg/day. The dose may be adjusted for a change in body weight of at least (plus \[+\]/minus \[-\]) 2 kilograms (kg) from baseline at the Month 6 study visit or for a change in insulin-growth factor-1 (IGF-1), as per investigator assessment.
Study: NCT04179396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Oral rucaparib will be administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Oral rucaparib will be administered twice daily
Study: NCT04179396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be administered once daily.~Enrollment into Arm A will be prioritized over Arm B until the objectives for Arm A have been achieved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone will be administered once daily with prednisone
Study: NCT02774018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) program
Study: NCT01924286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01963455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: paraurethral injection of MDCs
Description: MDCs transplantation by paraurethral injection .
Study: NCT01667822

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continued self help CBT
Description: After the initial Guided self help, patients in this arm continue the same self help program with 1 additional guiding session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual CBT
Description: After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.
Study: NCT02812381

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: KT
Description: to aplicate neuromuscular bandage technique(KT)
Study: NCT02596893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02812381

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCS
Description: To aplicate strain-counterstrain above trigger point
Study: NCT02941159

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SF2000SD
Description: This is an intergrase inhibitor

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00220844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desipramine
Study: NCT02580825

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback gait retraining
Description: Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). During the meeting, participant will receive biofeedback that will displayed on a computer screen that shows the forces that develop in the knee joint so that the patient can see graphically the forces that develop around the knee joint and will be guided / try to reduce the values of the graph by changing the intensity of his landing on the tracks. In all training the time that the biofeedback is shown will be reduced.
Study: NCT02596893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04957927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age
Description: Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age
Study: NCT02580825

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section).
Study: NCT01625338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: SOF 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: SOF 400 mg tablet administered orally once daily
Study: NCT00220844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Study: NCT00091195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Study: NCT02854826

Intervention type: OTHER
Intervention: SAFE Care model of care
Description: SAFE Care Model Site Intervention:~1. Endorse best practices for frail patients;~2. Identify frail patients promptly using multi-dimensional screening and assessments;~3. Employ interprofessional unit-based care team approach to frailty risk reduction during inpatient stay and create post-acute care transitions (PACT) plan recommendations;~4. Develop electronic health record templates for patient-centered interprofessional frailty notes;~5. Communicate PACT plans to primary care providers to promote safe transitions to the ambulatory setting and across the continuum of care.~6. Increase awareness, improve management of frailty, and improve overall health and well-being for adults who are frail or at risk of becoming frail.

Intervention type: OTHER
Intervention: SAFE Care model of care
Description: SAFE Care Model Site Intervention:~1. Endorse best practices for frail patients;~2. Identify frail patients promptly using multi-dimensional screening and assessments;~3. Employ interprofessional unit-based care team approach to frailty risk reduction during inpatient stay and create post-acute care transitions (PACT) plan recommendations;~4. Develop electronic health record templates for patient-centered interprofessional frailty notes;~5. Communicate PACT plans to primary care providers to promote safe transitions to the ambulatory setting and across the continuum of care.~6. Increase awareness, improve management of frailty, and improve overall health and well-being for adults who are frail or at risk of becoming frail.

Intervention type: OTHER
Intervention: SAFE Care model of care
Description: SAFE Care Model Site Intervention:~1. Endorse best practices for frail patients;~2. Identify frail patients promptly using multi-dimensional screening and assessments;~3. Employ interprofessional unit-based care team approach to frailty risk reduction during inpatient stay and create post-acute care transitions (PACT) plan recommendations;~4. Develop electronic health record templates for patient-centered interprofessional frailty notes;~5. Communicate PACT plans to primary care providers to promote safe transitions to the ambulatory setting and across the continuum of care.~6. Increase awareness, improve management of frailty, and improve overall health and well-being for adults who are frail or at risk of becoming frail.
Study: NCT01625338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: SOF 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN
Description: Peg-IFN 180 μg administered once weekly by subcutaneous injection
Study: NCT01760655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Allogeneic Lymphocytes
Description: Undergo DLI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic PBSCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic PBSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04078100

Intervention type: PROCEDURE
Intervention: Transseptal approach.
Description: surgical approach to the mitral valve through the Fossa Ovalis by way of the right atrium.
Study: NCT01395771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone call intervention, no phone call intervention
Description: Biweekly phone call intervention +routine service will be assigned to intervention group of new cases and old cases. Only routine service will be assigned to the control group of abovementioned two kind of cases.
Study: NCT02459587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crisis Line Facilitation (CLF)
Description: This single session therapist-delivered intervention addresses Veterans' perceived barriers and facilitators of crisis line use during periods of suicidal crisis. The CLF session culminates with the Veteran calling the Crisis Line with the therapist in the room as a way for the Veteran to practice the logistics of making the call and to have direct experiences that may counter any negative beliefs about Crisis Line use.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Those in the EUC condition received the same promotional items and information about the Veterans Crisis Line (VCL) as the CLF condition. Participants were encouraged to seek help via a provider or the VCL if they felt suicidal in the future. Research staff briefly explained key information about the VCL to those in the EUC condition (e.g., the links between the VCL and the VA, the 24/7/365 availability, etc.).